1. All Products
  2. DINJMERO - Meropenem
  3. MEROPENEM, 500mg, powder, vial
Public Pricelist

MEROPENEM, 500mg, powder, vial

https://unicat.msf.org/cat/product/34716
STD DINJMERO5V-

Valid Article

Former Code(s): DINJZNL0112 DINJZFR0203
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
5.1.6.1 - Medicines for bacterial central nervous system infections
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.2.2 - Watch group antibiotics
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.2.5 - Antituberculosis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J01DH02
Anatomical Therapeutic Chemical Classification according to WHOCC
PMF
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://www.unicat.msf.org/web/image/product.template/569214/image_1920?unique=6527827

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

MEROPENEM

Therapeutic Action

Antibacterial for systemic use, from carbapenem group

Broad spectrum antibiotic

Meropenem does not need to be combined with cilastatin, as it is metabolised through a different pathway.

Indications

Severe infections caused by Gram-positive and Gram-negative aerobic and anaerobic bacteria.

Complicated infections in children over 3 months of age.

Drug-Resistant Tuberculosis (DR-TB):

  • in children under 15 years and
  • if possible, in epileptic patients and/or those with TB meningitis.
Some restricted information has been hidden. Sign in to see this information

Instructions for use

Reconstitute the 500 mg powder vial with 10 ml of water for injection to obtain a reconstituted solution at 50 mg/ml meropenem. For the 1 g powder vial, reconstitute with 20 ml of water for injection.

The reconstituted solution must be given as deep IV infusion:

  • children < 20kg: in 5 ml/kg of 0.9% NaCl
  • children and adults > 20 kg: in 100 ml of 0.9% NaCl

Administer clavulanic acid PO 60 minutes prior to each dose of meropenem to prevent carbapenem resistance.

Precautions for Use

May cause gastrointestinal disturbances, neurotoxicity and hypersensitivity reactions.

Storage

  • Below 25ºC - Protect from sunlight
  • After reconstitution, use the solution immediately.